Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. InnoCare Pharma's Revenue for the
six
months ended in Dec. 2025 was €199.3 Mil. InnoCare Pharma's Total Assets for the quarter that ended in Dec. 2025 was €1,221.5 Mil. Therefore, InnoCare Pharma's Asset Turnover for the quarter that ended in Dec. 2025 was 0.16.
Asset Turnover is linked to ROE % through Du Pont Formula. InnoCare Pharma's annualizedROE % for the quarter that ended in Dec. 2025 was 18.68%. It is also linked to ROA % through Du Pont Formula. InnoCare Pharma's annualizedROA % for the quarter that ended in Dec. 2025 was 13.35%.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
InnoCare Pharma's annulizedROA % for the quarter that ended in Dec. 2025 is
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
InnoCare Pharma Asset Turnover Related Terms
InnoCare Pharma Asset Turnover Historical Data
* Premium members only.
The historical data trend for InnoCare Pharma's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:33C vs VRTX, REGN, RVMD: Asset Turnover Comparison
For the Biotechnology subindustry, InnoCare Pharma's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCare Pharma Asset Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InnoCare Pharma's Asset Turnover distribution charts can be found below:
* The bar in red indicates where InnoCare Pharma's Asset Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
InnoCare Pharma (STU:33C) has a Asset Turnover of 0.16 as of Dec. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on InnoCare Pharma and its competitors.
Is InnoCare Pharma's Asset Turnover too high?
InnoCare Pharma's current Asset Turnover is 0.16. Overall, InnoCare Pharma has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's Asset Turnover compare to VRTX and REGN?
InnoCare Pharma's Asset Turnover of 0.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on InnoCare Pharma and its competitors. InnoCare Pharma's current Asset Turnover is 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCare Pharma (STU:33C) is currently considered Possible Value Trap. The stock's GF Value™ is €2.29, compared to a current price of €1.51 — trading 34.1% below its estimated fair value. The current Asset Turnover is 0.16. InnoCare Pharma's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For InnoCare Pharma (STU:33C), the current Asset Turnover is 0.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCare Pharma (STU:33C) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued.
The current stock price of €1.51 is trading 34.1% below its estimated GF Value™ of €2.29.
GuruFocus considers InnoCare Pharma to be Possible Value Trap.
Key valuation signals for STU:33C:
Asset Turnover: 0.16
GF Value™: €2.29 vs. price of €1.51 (34.1% below fair value)
No single metric tells the full story. See the STU:33C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
78GF Score
Get the complete analysis for STU:33C
Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:33C has been successfully added to your 
